Summarized by Masters of Longevity from Longevity Technology.
A news article previewing clinical trial enrollment completion for a once-weekly injectable obesity therapy, and what readers can expect from the program.
Key Takeaways
- Kailera completed global Phase 3 enrollment for a once-weekly GLP-1/GIP dual‑agonist evaluated for weight loss over 76 weeks.
- The program includes three randomized, double‑blind, placebo‑controlled trials testing up to 10 mg subcutaneous dosing with dose titration and at least 52 weeks of maintenance.
- Primary efficacy is measured by percent change in body weight at Week 76 across diverse adult populations with and without type 2 diabetes.
